Advertisement

European Journal of Clinical Pharmacology

, Volume 69, Issue 11, pp 1981–1984 | Cite as

Towards a single VOICE for European clinical pharmacology: proposals for future developments

  • Jeffrey K. Aronson
  • Giampaolo Velo
Conference Report
In June 2012, 30 clinical pharmacologists from 19 different European countries met in the Ettore Majorana Foundation and Centre for Scientific Culture in Erice, Sicily, for an intensive 3-day meeting to discuss the future of clinical pharmacology in Europe. Here we summarize the main conclusions of that meeting. The countries from which the participants came are listed in Table  1. Although individuals from other countries were invited, they could not attend. Individuals from Belgium, Eire (the Republic of Ireland), and Russia sent written contributions.
Table 1

European countries and recognition of clinical pharmacology and therapeutics in those that are members of the European Union

Country

Represented at the meeting

Member of the EU [1]

CPT formally recognized (EU countries only)

Austria

No

Yes

No

Belgium

No

Yes

No

Bosnia Herzegovina

No

No

NA

Bulgaria

Yes

Yes

Yes

Croatia

Yes

Joining in 2013

Yes

Cyprus

No

Yes

No

Czech Republic

Yes

Yes

Yes

Denmark

Yes

Yes

Yes

Eire

No

Yes

Yes

Estonia

Yes

Keywords

Clinical Pharmacology European Medicine Agency Drug Policy Reimbursement System Regulatory Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We are grateful to all those who took part in the meeting. The following attended the meeting: Emil Gatchev (Bulgaria), Robert Likic (Croatia), Ivana Kacirova (Czech Republic), Milan Grundmann (Czech Republic), Stig Ejdrup Andersen (Denmark), Jeffrey Aronson (England), Michael Orme (England), James Ritter (England), Lembit Rago (Estonia), Risto Huupponen (Finland), Nicholas Moore (France), Eric van Ganse (France), Ingolf Cascorbi (Germany), Jens Jordan (Germany), Judit Kapocsi (Hungary), Giampaolo Velo (Italy), Roberto Padrini (Italy), Adam Cohen (Netherlands), Jan Schjøtt (Norway), Ewa Bałkowiec-Iskra (Poland), David Webb (Scotland), Momir Mikov (Serbia), Slobodan Jankovich (Serbia), Adriàn Llerena (Spain), Ylva Böttiger (Sweden), Folke Sjöqvist (Sweden), Mitsuku Kondo (Switzerland), Hakan Ergun (Turkey), Philip Routledge (Wales); the Chief Executive Officer of The British Pharmacological Society, Jonathan Bruun, also attended.

The first draft of this report was sent to all the participants and was amended in the light of their further comments. We are particularly grateful to Michael Orme and Folke Sjöqvist for extensive comments.

Confict of Interest statement

We are unaware of any actual or potential conflicts of interest in relation to this article.

Financial statement

The participants in this meeting funded their own attendance. The SK Foundation (Rome, Italy) is thanked for partial unrestricted support of the local organization.

References

  1. 1.
    European Union. Member countries of the European Union. Available at: http://europa.eu/about-eu/countries/index_en.htm. Accessed 3 May 2013
  2. 2.
    Aronson JK (2012) What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists. Br J Clin Pharmacol 73(2):161–169PubMedCrossRefGoogle Scholar
  3. 3.
    Aronson JK (2012) Finding a VOICE for UK clinical pharmacology. Br J Clin Pharmacol 73(6):843–845PubMedCrossRefGoogle Scholar
  4. 4.
    European Association for Clinical Pharmacology and Therapeutics. Available at: http://www.eacpt.org. Accessed 3 May 2013
  5. 5.
    Aronson JK (2004) On being 30. Br J Clin Pharmacol 57(1):1–5CrossRefGoogle Scholar
  6. 6.
    Dahlqvist R (2008) The European Journal of Clinical Pharmacology: 40 years young and going strong. Eur J Clin Pharmacol 64(2):95–96PubMedCrossRefGoogle Scholar
  7. 7.
    Eu2P. European Programme in Pharmacovigilance and Pharmacoepidemiology. Available at: http://www.eu2p.org. Accessed 3 May 2013
  8. 8.
    Aronson JK (2010) A manifesto for clinical pharmacology from principles to practice. Br J Clin Pharmacol 70(1):3–13PubMedCrossRefGoogle Scholar
  9. 9.
    Orme M, Sjöqvist F (eds); Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rägo L, Rawlins M, Reidenberg M, Sjöqvist F, Smith T, Thüermann P, Walubo A (contributors) (2010) Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 107(1): 531–59Google Scholar
  10. 10.
    Orme M, Sjöqvist F, Birkett D (eds); Abernethy D, Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Hoppu K, Maxwell S, Orme M, Rägo L, Rawlins M, Reidenberg MK, Sjöqvist F, Smith T, Thüermann P, Walubo A (contributors) (2012). Clinical pharmacology in research, teaching and health care. CIOMS/IUPHAR/WHO. Available at: http://www.cioms.ch/index.php/publications/printablepublications?task=view&id=46&catid=58. Accessed 3 May 2013
  11. 11.
    Mucklow J, Bollington L, Maxwell S (2012) Assessing prescribing competence. Br J Clin Pharmacol 74(4):632–639PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Primary Care Health SciencesNew Radcliffe HouseOxfordUK
  2. 2.Section of Pharmacology, Department of Public Health and Community Medicine, University Hospital Policlinico G.B. RossiUniversity of VeronaVeronaItaly

Personalised recommendations